Memorial Sloan Kettering is dedicated to providing our patients with individualized care based on their specific needs and our unique expertise. We aim to ensure that all patients receive only what will be best for them and avoid unnecessary tests or treatments.
The Evidence-based Cancer Imaging Program, which develops and implements standards for the use of advanced imaging tests, helps us to achieve that goal.
The Protecting Access to Medicare Act (PAMA) 2014 requires healthcare professionals to consult appropriate use criteria (AUC) when ordering advanced diagnostic imaging tests such as CT scans, MRIs, PET scans or nuclear medicine scans, beginning January 1, 2020. MSK has been designated a qualified provider led entity (QPLE) by the Centers for Medicare and Medicaid Services (CMS) in accordance with regulation 42 CFR 414.94. The imaging and treatment requirements for cancer patients are very different from those for other patients. MSK was the first dedicated cancer center in the U.S. to receive this designation from CMS. As a QPLE, MSK is empowered to create, modify, or endorse criteria for ordering advanced diagnostic imaging tests specific to the needs of patients with cancer.
In the Evidence-based Cancer Imaging Program, the AUC used at MSK are continually evaluated by teams of experts to ensure that they reflect the latest scientific evidence, state-of-the-art clinical practice, and the particular needs of cancer patients. (View our methodology).
Our comprehensive approach incorporates science, value, and expertise to ensure that all our patients receive the exact imaging studies that they require and that will be most beneficial to their needs.